“…enabling disclosure of an invention it must be possible to make a reasonable prediction that the invention will work (Regeneron [v Genentech[2013] EWCA Civ 93, [2013] RPC 28] paragraph 100). In the context of an invention which includes the achievement of a therapeutic effect as one of its features, absolute proof is not required b…”
“…Finally we should mention the decision of the Court of Appeal in Regeneron Pharmaceuticals Inc v Genentech Inc [2013] EWCA Civ 93, [2013] RPC 28, to which the judge referred. This appeal concerned a patent claim directed to the use of a human vascular endothelial growth factor (“hVEGF”) antagonist, such…”